© Copyright 2025 American Medical Association. All rights reserved.
A therapeutic apheresis procedure is utilized to selectively delipidate high-density lipoprotein (HDL) cholesterol and subsequently reinfuse the treated plasma back into the patient. This advanced medical intervention is particularly relevant for patients experiencing acute coronary syndrome, which may present as unstable angina or non-ST-segment elevation myocardial infarction. The process of apheresis involves the extraction of whole blood from the patient, which is then subjected to a centrifugation technique that separates the blood components. During this procedure, the alpha HDL is transformed into a pre-beta-like HDL, a variant that is more effective in facilitating the removal of lipids from arterial plaque. The conversion to pre-beta-like HDL is significant as it enhances the transport of cholesterol to the liver, thereby contributing to a reduction in atherosclerosis within the blood vessels. This reduction in atherosclerosis is crucial for lowering the risk of developing further cardiovascular complications. The procedure begins with establishing venous access, after which the patient is connected to a specialized machine designed for apheresis. This machine not only separates the blood cells but also incorporates organic solvents to effectively delipidate the HDL. Finally, the modified plasma, now containing the altered HDL, is reinfused back into the patient, completing the therapeutic process.
© Copyright 2025 Coding Ahead. All rights reserved.
The therapeutic apheresis with selective HDL delipidation and plasma reinfusion is indicated for specific cardiovascular conditions. The primary indications include:
The procedure involves several critical steps to ensure effective treatment. Each step is designed to facilitate the safe and efficient delipidation of HDL cholesterol.
Post-procedure care involves monitoring the patient for any immediate adverse reactions to the apheresis process. Patients may be observed for changes in vital signs and any signs of complications related to venous access or the reinfusion of plasma. It is also important to assess the patient's overall response to the treatment, including any improvements in symptoms related to acute coronary syndrome. Follow-up appointments may be scheduled to evaluate the long-term effectiveness of the procedure and to monitor lipid levels and cardiovascular health.
| Short Descr | THXP APHERESIS W/HDL DELIP | Medium Descr | THERAPEUTIC APHERESIS W/SELECTIVE HDL DELIP | Long Descr | Therapeutic apheresis with selective HDL delipidation and plasma reinfusion | Status Code | Carriers Price the Code | Global Days | YYY - Carrier Determines Whether Global Concept Applies | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Procedure or Service, Not Discounted when Multiple | ASC Payment Indicator | Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight. | Berenson-Eggers TOS (BETOS) | T2D - Other tests - other | MUE | 1 |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2015-01-01 | Added | First appearance in code book |
| 2014-01-01 | Added | Added |
Get instant expert-level medical coding assistance.